WINNERS & LOSERS: NARF has contract cancelled; Headlam reviews options
(Alliance News) - The following are the leading risers and fallers among London Main Market small-cap and AIM stocks on Friday. Read More
| Price | 3.75p on 04-08-2026 at 08:51:36 |
|---|---|
| Change | -0.20p -5.06% |
| Buy | 3.80p |
| Sell | 3.70p |
| Last Trade: | Sell 250,000.00 at 3.71p |
| Day's Volume: | 1,537,814 |
| Last Close: | 3.95p |
| Open: | 3.90p |
| ISIN: | GB00BYV81293 |
| Day's Range | 3.75p - 3.90p |
| 52wk Range: | 3.75p - 12.35p |
| Market Capitalisation: | £40.11m |
| VWAP: | 3.777639p |
| Shares in Issue: | 1.07b |
Sector: Medicine and Biotech
Listed In: FTSE AIM All-Share,
Shield Thera (STX) Latest Trades |
||||
| Buy/Sell | Volume | Trade Prc | Trade Type | Trade Time |
|---|---|---|---|---|
| Sell* | 250,000 | 3.71p | Ordinary |
09:51:35 - 04-Aug-26 |
| Unknown* | 25,000 | 3.75p | Ordinary |
09:51:20 - 04-Aug-26 |
| Buy* | 200 | 3.80p | SI Trade |
09:51:20 - 04-Aug-26 |
| Buy* | 90 | 3.80p | SI Trade |
09:51:20 - 04-Aug-26 |
| Sell* | 250,000 | 3.72p | Ordinary |
09:51:16 - 04-Aug-26 |
| Sell* | 250,000 | 3.72p | Ordinary |
09:51:00 - 04-Aug-26 |
| Buy* | 3,000 | 3.90p | SI Trade |
09:43:26 - 04-Aug-26 |
| Buy* | 280 | 3.90p | SI Trade |
09:43:26 - 04-Aug-26 |
| Buy* | 100 | 3.90p | SI Trade |
09:43:26 - 04-Aug-26 |
| Buy* | 6,739 | 3.90p | SI Trade |
09:43:26 - 04-Aug-26 |
Shield Thera (STX) Regulatory News |
||
| Date | Source | Headline |
|---|---|---|
| 3rd Aug 2026 12:02 pm | RNS | Total Voting Rights |
| 30th Jul 2026 7:00 am | RNS | Q2 and H1 2026 Trading Update |
| 28th Jul 2026 7:00 am | RNS | ACCRUFeR® Phase 3 pediatric trial published |
| 30th Jun 2026 7:52 am | RNS | Block Listing 6 Monthly Return |
| 18th Jun 2026 4:20 pm | RNS | Results of 2026 Annual General Meeting |
| 29th May 2026 9:11 am | RNS | Total Voting Rights |
| 5th May 2026 7:00 am | RNS | Grant of Share Options |
| 1st May 2026 7:00 am | RNS | Q1 2026 Trading Update |
| 30th Apr 2026 7:01 am | RNS | Total Voting Rights |
| 27th Apr 2026 7:00 am | RNS | Enrollment in Phase II Clinical Trial for ACCRUFeR |